What the FDA labels say about taking them together
Adalimumab and adalimumab-adbm
Adalimumab-adbm's FDA label of May 22, 2026 names adalimumab in its boxed warning section; the adalimumab labels PlainMeds reads (4) do not name adalimumab-adbm. The adalimumab-adbm label: “Although MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either CYLTEZO or MTX.”
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); the adalimumab-adbm FDA label on DailyMed (effective May 22, 2026, Boehringer Ingelheim Pharmaceuticals, Inc.).
What does the adalimumab label say about adalimumab-adbm?
Adalimumab's label (effective October 21, 2025) and its 3 other brand-application labels do not name adalimumab-adbm in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
What does the adalimumab-adbm label say about adalimumab?
Adalimumab-adbm label, boxed warningSERIOUS INFECTIONS Patients treated with adalimumab products, including CYLTEZO, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ].
Adalimumab-adbm label, drug interactionsAlthough MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either CYLTEZO or MTX [see Clinical Pharmacology (12.3) ].
Adalimumab-adbm label, warnings and precautionsPatients treated with adalimumab products, including CYLTEZO, are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.
Source: FDA drug label (Cyltezo), Boehringer Ingelheim Pharmaceuticals, Inc., effective May 22, 2026 (SPL set 115ea79b-7209-7f19-b35d-36ec0828fbf5), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adalimumab | Adalimumab-adbm | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Psoriasis, Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1,587.82 per mL 40 mg/0.4 mL | $639.19 per pen 40 mg/0.4 mL |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once